GUIDELINE FOR ACUTE MYELOID LEUKAEMIA
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation | Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome - Clinical Lymphoma, Myeloma and Leukemia
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML) - Silvia Park, Daehun Kwag, Tong Yoon Kim, Jong Hyuk Lee, Joon yeop Lee,
Results of FLAG-IDA in 23 adult refractory/relapsed ALL patients | Download Table
Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Re | CEOR
FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia - Shahswar - 2020 - British Journal of Haematology - Wiley Online Library
FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia - Shahswar - 2020 - British Journal of Haematology - Wiley Online Library
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia
IJMS | Free Full-Text | Increasing Role of Targeted Immunotherapies in the Treatment of AML | HTML
PDF) FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia
FLAG-Ida for Acute Myeloid Leukaemia (AML)
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia | Journal of Clinical Oncology
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. - Abstract - Europe PMC
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome - Clinical Lymphoma, Myeloma and Leukemia
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML) - Silvia Park, Daehun Kwag, Tong Yoon Kim, Jong Hyuk Lee, Joon yeop Lee,
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (2000)-FLUDARABINE-IDARUBICIN (FLA-IDA) In-Patient Regimen Regimen •
FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia - Shahswar - 2020 - British Journal of Haematology - Wiley Online Library
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia | Journal of Clinical Oncology
NSSG Chemotherapy Protocol
Frontiers | Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
AML Hub on Twitter: "🎙️Want to hear more on this subject? We have the perfect podcast for you! #leusm #leukemia https://t.co/PZWcarh0XB" / Twitter
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial -
Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Re | CEOR
